Implementation of A Multi-Disciplinary Team Focused on Providing Comprehensive Care for Patients Suffering from Vaping-Related Illness

Parikh, Raj; Belok, S.H.; O'Donnell, Barry; Wakeman, C.; Mishuris, Rebecca G.; Potter, Jennifer; Hawkins, F.J.; Cohen, Robyn T.; Kathuria, Hasmeena

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1077

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Outside of the short-term complications following a diagnosis of EVALI, much is unknown about the longterm sequela of the disease process. Therefore, follow-up evaluation with a Pulmonology specialist as well as addiction counseling may be warranted and establishing a multi-disciplinary program to provide comprehensive care for EVALI patients, as well as routine subjective and objective monitoring, is crucial [56].…”

Section: Discharge and Follow-upmentioning

confidence: 99%

E-cigarette, or vaping, product use-associated lung injury: a review

et al. 2020

View full text Add to dashboard Cite

Background E-cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) is a disease entity related to the use of battery-operated or superheating devices that create an aerosolized form of nicotine and tetrahydrocannabinol (THC) and/or other substances for inhalation. Methods We performed a literature review to document epidemiology, pathogenesis and risk factors, diagnosis, clinical presentation, evaluation and management of EVALI. Results In the summer of 2019, an outbreak of EVALI cases brought this disease entity into the national spotlight. Since being recognized as a serious pulmonary disease with public health implications, more than 2600 cases have been reported to CDC with 68 deaths as of February 2020. The pathophysiology of EVALI remains unknown. Substances such as Vitamin E acetate have been implicated as a possible causes of lung injury. The CDC has established case definitions of “confirmed EVALI” cases to help guide identification of the disease and assist in surveillance. While clinical judgement by healthcare providers is imperative in the identification of EVALI cases, the heterogeneous presentations of EVALI make this difficult as well. Ultimately most investigative studies should be aimed at ruling out other disease processes that can present similarly. Treatment is centered around removing the offending substance and providing supportive care. Conclusions EVALI is a serious pulmonary disease with public health implications. Diagnosis requires a high degree of suspicion to diagnose and exclusion of other possible causes of lung disease. It may be beneficial to involve a pulmonary specialist early in the management of this disease which is generally supportive care.

show abstract

Section: Discharge and Follow-upmentioning

confidence: 99%